Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Adherex Technologies, Inc.
With
US Oncology Research
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed written informed consent
Male and female patients \> or = 18 years of age with a solid tumor(s) that is locally advanced or metastatic for which single agent carboplatin, or docetaxel or capecitabine would be appropriate
Measurable disease
Immunohistochemical evidence of N-cadherin expression in tumor tissue
Adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and ECG
You may not be if
Receipt of ADH-1 prior to this clinical study
Chemotherapy, radiotherapy, or any other investigational drug within 4 weeks before study entry
History of spinal cord compression, or history of primary brain tumor(s) or brain metastases (known or suspected) unless any lesions have completely resolved following appropriate treatment and there has been no recurrence for at least 6 months
History of tumors that have shown clinically significant evidence of active bleeding within 12 weeks before study entry
Stroke, major surgery, or other major tissue injury within 4 weeks before study entry
Uncontrolled congestive heart failure, coronary artery disease, or life threatening arrhythmias; myocardial infarction within 12 months; significant electrocardiogram (ECG) abnormalities, or known hypercoagulable states
Clareo Health | A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine
